Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NEW ZEALAND STOCK EXCHANGE  >  AFT Pharmaceuticals Ltd    AFT   NZAFTE0001S4

AFT PHARMACEUTICALS LTD

(AFT)
  Report
SummaryNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

AFT Pharmaceuticals : secures Maxigesic® IV distribution in Indonesia

share with twitter share with LinkedIn share with facebook
share via e-mail
0
12/10/2019 | 06:41pm EST
December 11, 2019

AFT Pharmaceuticals (NZX; AFT, ASX; AFP) has signed an exclusive distribution agreement for the registration and commercialisation of Maxigesic IV® in Indonesia with the Jakarta-based PT Dankos Farma.

PT Dankos Farma is a subsidiary of Kalbe Farma Tbk., the largest publicly listed pharmaceutical company in Southeast Asia.

AFT Managing Director Dr Hartley Atkinson, says the agreement kicks off the process of commercialisation for Maxigesic IV® in Indonesia, which has a total analgesic market worth US$530m.*

'We are pleased to further grow our distributor network and expand the company's partnerships for Maxigesic IV® in South East Asia. We are looking forward to working with PT Dankos Farma to make the most of the strong potential we see in Indonesia for Maxigesic IV®'.

AFT and PT Dankos Pharma will shortly file for regulatory approval for Maxigesic IV®, a process that is expected to take around two years to complete. Following registration, Maxigesic IV® will be commercialised through Kalbe Farma's strong marketing, branding and distribution expertise.

For and on behalf of AFT Pharmaceuticals Limited, Malcolm Tubby, CFO.

For more information:

Investors
Dr Hartley Atkinson
Managing Director
AFT Pharmaceuticals
Tel: +64 9488 0232

Media
Richard Inder
The Project
Tel: +64 21 645 643

Notes to editors:

Maxigesic IV® is an intravenous form (paracetamol 1000 mg and ibuprofen (as sodium dihydrate) 300 mg) of AFT's patented Maxigesic pain relief medicine. It has been developed as a line extension to Maxigesic tablets, for post-operative pain relief in hospitals where patients cannot take an oral pain relief medicine such as Maxigesic.

*Source: Statista, October 2019

About AFT Pharmaceuticals

AFT is a growing multinational pharmaceutical company that develops, markets and distributes a broad portfolio of pharmaceutical products across a wide range of therapeutic categories which are distributed across all major pharmaceutical distribution channels: over-the-counter (OTC), prescription and hospital. Our product portfolio comprises both proprietary and in-licensed products, and includes patented, branded and generic drugs. Our business model is to develop and in-license products for sale by our own dedicated sales teams in our home markets of Australia and New Zealand and in certain Southeast Asian markets, and to out-license our products to local licensees and distributors to over 125 countries around the world. For more information about the company, visit our website www.aftpharm.com.

Disclaimer

AFT Pharmaceuticals Limited published this content on 11 December 2019 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 December 2019 23:40:06 UTC

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AFT PHARMACEUTICALS LTD
2019SECISSUE : AFT: Amended Capital Change Notice Opens in a new Window
PU
2019AFT PHARMACEUTICALS : Appendix 3B Opens in a new Window
PU
2019AFT PHARMACEUTICALS : secures Maxigesic® IV distribution in Indonesia
PU
2019AFT PHARMACEUTICALS : secures Maxigesic IV distribution in Indonesia Opens in a ..
PU
2019AFT PHARMACEUTICALS : Welcomes new codeine medicine restrictions
AQ
2019AFT PHARMACEUTICALS : Maxigesic to launch in canada in 2020
AQ
2019AFT PHARMACEUTICALS : Letter to Shareholders Opens in a new Window
PU
2019BIOSYENT : Signs Exclusive Agreement for Pain Management Products
AQ
2019AFT PHARMACEUTICALS : Financial results for half year ended 30 september 2019
AQ
2019AFT PHARMACEUTICALS : Financial Results For Half Year Ended 30 September 2019
PU
More news
Financials (NZD)
Sales 2020 103 M
EBIT 2020 21,4 M
Net income 2020 9,52 M
Debt 2020 43,6 M
Yield 2020 -
P/E ratio 2020 39,5x
P/E ratio 2021 22,6x
EV / Sales2020 4,12x
EV / Sales2021 3,34x
Capitalization 380 M
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus UNDERPERFORM
Number of Analysts 2
Average target price 3,45  NZD
Last Close Price 3,85  NZD
Spread / Highest target -10,4%
Spread / Average Target -10,4%
Spread / Lowest Target -10,4%
EPS Revisions
Managers
NameTitle
Hartley Atkinson Chief Executive Officer, Executive Director & MD
David Mark Flacks Chairman
Malcolm Tubby Chief Financial Officer & Secretary
Douglas John Wilson Independent Non-Executive Director
Marree Atkinson Executive Director & Chief of Staff
Sector and Competitors
1st jan.Capitalization (M$)
AFT PHARMACEUTICALS LTD249
JOHNSON & JOHNSON0.78%385 622
ROCHE HOLDING AG2.21%283 936
MERCK AND COMPANY0.25%228 960
PFIZER3.65%221 752
NOVARTIS-0.29%215 061